- Original basic research
- Open Access
Platelet adhesion onto immobilized fibrinogen under arterial and venous in-vitro flow conditions does not significantly differ between men and women
© Loncar et al; licensee BioMed Central Ltd. 2007
- Received: 24 January 2007
- Accepted: 26 April 2007
- Published: 26 April 2007
Gender-related differences in incidence of arterial thrombosis have been a focus of interest for years. The platelet integrin αIIbβ3 is primarily responsible for the interaction between platelets and fibrinogen and consecutive thrombus growth. In this study, we evaluated platelet adhesion onto immobilized fibrinogen under venous and arterial flow conditions in men and women.
Platelets in whole anticoagulated blood were labelled with the fluorescence dye Mepacrine and perfused through the rectangular flow chamber over glass cover slips coated with fibrinogen (shear rates of 50 s-1, 500 s-1 and 1500 s-1). A fluorescence laser-scan microscope was used for visualisation and quantification of platelet adhesion at 15 seconds, 1 and 5 minutes after the start of perfusion.
During perfusion, the platelet adhesion linearly increased in regard to exposition time and shear rate. After five minutes of perfusion the platelet adhesion onto immobilized fibrinogen showed no significant gender related difference, neither at 50 s-1 nor at 500 s-1 and 1500 s-1 (p > 0.05), respectively. No significant difference in platelet adhesion onto immobilized fibrinogen, in regard to the menopausal status, was either observed (p > 0.05).
In our in vitro experimental system, hormonal differences between men and women did not influence platelet adhesion onto immobilized fibrinogen, neither under venous nor under arterial rheological conditions.
- Shear Rate
- Platelet Adhesion
- Arterial Thrombosis
Ischemic heart and cerebrovascular disease are leading causes of morbidity and mortality in the western world and are steadily increasing incidence in the third world as well [1, 2]. Epidemiological studies  indicate that these diseases result from complex interactions between genetic susceptibility factors, chronic environmental influences (e.g. hormonal imbalance, smoking, obesity) and established, intercurrent disorders (e.g. diabetes, hypertension, dyslipidemia, or hyperhomocysteinemia). The most devastating complication of these disorders is acute myocardial infarction or stroke resulting from the formation of occlusive thrombus at the site of ruptured atherosclerotic plaque [1–4]. Platelet-dependent thromboembolism is an underlying mechanism of arterial thrombosis and the critical role of platelets in this process is now widely accepted [1, 5]. Its participation in the arterial thrombosis is centered on their adhesive properties and their ability to respond to stimuli with rapid activation and, as end effect, aggregation [5, 6].
It has been well known that the incidence of arterial thrombotic events in women is generally lower compared to that in men. It was our initial point to speculate about beneficial effects of female sexual hormons in regard to the incidence of arterial thrombosis and one of the reasons for non-critical and non-selective inducing estrogen replacement therapy (ERT). Although several studies have demonstrated that postmenopausal women who take ERT show decreased incidence of arterial thrombosis compared to those without ERT , there has been no clear epidemiological evidence for decrease in a thrombotic risk. All these reports of beneficial effects of estrogen are based on the retrospective studies and a small number of controlled clinical trials. Recently conducted clinical trials have shown ERT could also be associated with adverse arterial vascular events [8–10]. It seems that risk and benefit effect of estrogen is also dose dependent. However, the possible mechanism and efficiency of estrogen mediated antithrombotic or prothrombotic action is still a controversial issue.
Arterial thrombosis is initiated by platelet activation, but the in-vivo effects of estrogens on a platelet function have not been well understood. Platelet membrane integrin αIIbβ3 (glycoprotein GP IIb–IIIa) has an important role in platelet adhesion and aggregation through binding of a variety of circulating and immobilized ligands including fibrinogen under different shear stress conditions [5, 6, 11, 12]. However, when platelets are activated by various stimuli, the platelet αIIbβ3 undergoes a conformational change and provides a high-affinity binding site for a soluble fibrinogen. The fibrinogen acts as a bridging molecule between pairs of αIIbβ3 molecules in adjacent activated platelets [5, 6, 13]. On the other side, the interaction between immobilized fibrinogen and platelets does not require previous platelet activation or conformational changes of platelet αIIbβ3 and has been shown to occur even in the presence of platelet inhibitors . An immobilized fibrinogen can be found on the injured surface of vascular endothelium, atherosclerotic plaques and vascular prostheses, where it is the major ligand mediating platelet thrombus growth on artificial surfaces [5, 6]. This study, conducted under strictly controlled experimental venous and arterial environmental conditions, was undertaken to determine whether platelet adhesion in healthy individuals, mediated through the integrin αIIbβ3, was depending on the gender-related hormonal status.
Descriptive statistical data related to participant's gender, age, haemostaseology and biochemical parameters
46 ± 12
41 ± 10
37 ± 3
41 ± 2
285 ± 71
231 ± 60
146 ± 20
124 ± 20
141 ± 22
125 ± 27
140 ± 46
116 ± 32
174 ± 109
119 ± 34
179 ± 105
172 ± 103
164 ± 69
133 ± 74
126 ± 24
116 ± 27
138 ± 34
122 ± 24
111 ± 25
101 ± 32
113 ± 16
98 ± 8
127 ± 16
108 ± 19
120 ± 21
112 ± 16
92 ± 18
105 ± 15
110 ± 14
108 ± 12
156 ± 99
197 ± 110
199 ± 36
190 ± 37
124 ± 28
108 ± 25
52 ± 18
39 ± 10
0.6 ± 0.5
0.5 ± 0.6
60 ± 34
101 ± 49
10 ± 7
26 ± 19
9 ± 4
10.5 ± 4
104 ± 8
99 ± 7
304 ± 50
243 ± 51
Excessive smokers, overweight donors, donors with a family history of neoplastic, arterial or venous vessels disease were excluded from the study. Experimental protocols were reviewed and approved by the local ethics committee and meet the standards of the Declaration of Helsinki.
Blood taken from the cubital vein was immediately anticoagulated with PPACK (D-Phenylalanyl-L-prolyl-L-arginine chloromethyl ketone) at a final concentration of 40 μM. Platelets were labelled with the fluorescence dye Mepacrine (quinacrine dihydrochloride, final concentration 10 μM; Sigma Chemical, 60 min at 37°C). The dye immediately accumulates in the delta granules of platelets without influencing a platelet physiology . Blood was used within two hours of its withdrawal.
Binding specificity of platelets to immobilized fibrinogen was tested with two additional experimental designs. In the first experimental set, a specificity of platelet adhesion onto immobilized fibrinogen was tested in flow experiments using glass coverslips co-coated with bovine serum albumin (BSA, 5 μg/mm2, n = 3). In the second set of experiments (n = 3) a blood was additionally incubated with Abciximab (c7E3, 4 μg/mL for 10 min, 37°C) and perfused over fibrinogen coated coverslips. c7E3 Fab is a chimeric human/mouse Fab fragment derived from the murine monoclonal 7E3 antibody (c7E3, Centocor Inc. Leiden, Niederland) that binds selectively to the αIIbβ3 .
Screening parameters and factors of coagulation were assessed with commercial hemostatic high-speed analyzers and kits for clotting as well as chromogenic and immunologic coagulation assays (BCT® and BCS®, Dade-Behring, Marburg Germany). Both systems measure coagulation capabilities of plasma from blood collected using a 3.8% sodium citrate as anti-coagulant.
All subjects were genotyped for the β3 polymorphism of αIIbβ3 (Leucine-Proline substitution at amino acid 33) by polymerase chain reaction amplification of genomic DNA followed by restriction enzyme digestion (polymerase chain reaction-restriction fragment length polymorphism), as published previously .
Preparation of fibrinogen-coated cover slips
Suspensions of human fibrinogen (Sigma-Aldrich) were prepared as previously described . Glass cover slips (24 × 50 mm) were coated with 50 μl of fibrinogen solution (2,5 mg/mL). The cover slip was placed in a humid environment (60 min at 37°C) to allow the protein to adhere to the glass surface. The coated cover slips were rinsed with 10 mL of 50 mmol/L phosphate buffered saline (pH 7.35) to remove non-adherent fibrinogen and were placed into the flow chamber. Fibrinogen density on the glass surfaces was calculated to be 0.1 μg/mm2. For control experiments, three cover slips were coated with bovine serum albumin. Glass surfaces density of bovine serum albumin was calculated to be of 5 μg/mm2.
Flow chamber and laser-scan microscopy
Platelet adhesion rate onto fibrinogen-coated glass cover slips was conducted in the rectangular flow chamber  under linear shear rate of 50 s-1, 500 s-1 and 1500 s-1, respectively.
One side of the parallel flow chamber was formed by a fibrinogen coated glass cover slip with a flow path height of 50 μm, determined by Teflon gasket. Assembled flow chambers were filled with phosphate buffered saline (pH 7.35). According to the Newtonian fluid axiom, a shear stress is constant and dependent on the flow rate. Shear rate of 50 s-1 represents venous environment, share rate of 500 s-1 mimics wall shear rate of larger arteries; shear rate of 1500 s-1 represents a typical arteriolar shear rate as well as shear rate in moderate arterial stenosis . An epifluorescence laser-scan microscope (Axiovert 100 M, Carl-Zeiss, Jena, Germany) allowed a real-time visualisation of labelled platelets during perfusion through the chamber. To assess the time-course of platelet adhesion, series of images (five images per series, 0,7 s per image) were recorded at 0, 1 and 5 minutes. The zero time point represents 15 seconds after the start of perfusion (Perfusor, B. Braun, Meslingen, Germany). Image analysis was performed using the ImageJ software (version 1.26t, NIH, USA). This program allows evaluation of platelet-surface interaction, consecutive aggregation and evaluation of thrombus generation at one exactly defined area in each image. A single frame image corresponds to the area of 980 × 980 μm. The stable attached platelets (expressed as fluorescence) were defined as those, which remain at their initial adhering position in the first and second image (time frame of 0.7 sec). Platelets were considered to move on the surface when exhibiting spatial displacement greater than a diameter of one platelet. To estimate the motion, a series of 5 images (time frame 0.7 sec) at one time point was made. Using ImageJ software, images were digitalized and a threshold was applied to distinguish platelet from background. The first two consecutive frames in a series were superimposed using the logical AND function. The resulting image represented only the overlapping areas of single platelets at two different time points.
Calculations and statistics
Data in this study are given as mean values ± SD. Absolute fluorescence was expressed as arbitrary units (pixel units) and represents sum of fluorescence of each thrombus or individual adherent platelet in one defined area. Only platelets showing a stable adherence during one series of image were taken into calculation. Platelet adhesion was calculated using the logic function of the applied software (ImageJ) and represents stable adhesion of platelets between the first and second image. To reduce the influence of inter-individual variation, data were normalized (absolute fluorescence recorded after five minute of perfusion was divided by the recorded fluorescence after one minute) and expressed as a relative adhesion. The relative adhesion represents an increase of absolute fluorescence as a function of time.
Differences between experimental groups were tested by Student's t-test (two-sided). Regression analyses were based on individual measurements using Spearman's rank correlation coefficient. Statistical analyses were performed using SPSS for Windows, version 6.0.1. P-value of less than 0.05 (two-sided) was taken to indicate a significant difference.
A specificity of binding of platelets to immobilized fibrinogen in experimental in vitro system was tested with blood preincubated with Abciximab. A perfusion of five minutes (1500 s-1) of Abciximab preincubated blood over fibrinogen-coated cover slips showed no significant adherence of platelets (absolute fluorescence of stable adherent platelets: 168 U ± 35 U vs. 50535 U ± 21552 U in control experiments, p < 0.05). Similarly, perfusion over BSA-coated glass cover slips falled to show significant platelet adherence.
The baseline characteristics of the study participants are summarized in the Table 1 Age average was 44 ± 12 years and did not significantly differ between men and women (41 ± 10 vs 46 ± 12 years, p > 0.05), respectively. Biochemical parameters and factors of coagulation were within the normal range in all participants. Men showed a significantly higher value of haematocrit and women higher platelet count. A significant difference between men and women was observed for Fll, FXII and FXIII. Additional analysis indicated that these differences did not influenced platelet adhesion onto immobilized ligand. All other parameters of plasmatic haemostasis as well as biochemical parameters did not differ significantly.
Platelet adhesion (mean ± SD) onto immobilized fibrinogen expressed as absolute fluorescence (AU) related to the gender, shear rate and perfusion time.
Shear rate and perfusion time
Platelet adhesion, AU
venose shear rate, 50 s-1
2408 ± 1697
2965 ± 1537
5857 ± 2581
7235 ± 3387
9364 ± 4588
11324 ± 5114
arterial shear rate 500 s-1
3426 ± 1744
3408 ± 1578
9949 ± 3580
12915 ± 8963
31980 ± 11246
44474 ± 18095
arterial shear rate 1500 s-1
2503 ± 1227
3392 ± 1826
12015 ± 4571
14161 ± 5018
47665 ± 18504
53404 ± 24797
Taking into consideration that platelet adhesion and platelet detachment after initial adhesion is a dynamic process, dependent from shear rate and perfusion time and to avoid inter-individual variation data were normalized (see Statistics).
Relative platelet adhesion onto immobilized fibrinogen related to the gender and shear rate.
R. a. 50 s-1
R. a. 1500 s-1
4.72 ± 2.05
1.94 ± 1.31
5.39 ± 2.40
4.09 ± 1.40
3.02 ± 2.15
1.60 ± 0.39
4.56 ± 1.44
3.85 ± 1.31
However, in our study, platelet adhesion did not exhibit a significant difference between men and women (p > 0.05.), neither expressed as an absolute adhesion nor expressed as a relative adhesion. Further evaluation showed no significant relationship between examined variables (see Table 1), neither in men nor in women. None of indicated parameters significantly correlated with platelet adhesion.
Nevertheless, no significant correlation was found between the platelet adhesion and age, when related to gender (p > 0.05).
Experiments with immobilized collagen were conducted together with experiments with fibrinogen (data are not showed) and the relationship between gender related platelet adhesion onto immobilized collagen in regard to the shear rate and time of perfusion was carefully evaluated. Between males and females, neither significant difference nor constant trend could be found in regard to the platelet adhesion. The analysis of normalized data obtain similar results.
After the menopause, the risk of cardiovascular disease in women increases to equal the risk in men, which makes a rationale for implementation of estrogen replacement therapy (ERT). Paradoxically, the use of estrogen itself could also be associated with a thromboembolic disease in women on oral contraception as well as in men treated with diethylstilbestrol for prostate cancer [18, 19]. Although the estrogen has been clinically available for more than six decades, there has been some confusion defining the risks and benefits of menopausal ERT [8–10]. Reagrding the central role of platelets in arterial thrombosis, it was hypothesized that a hormonal status could have a significant impact on platelet adhesion. Following the observation of gender-dependent difference in incidence of arterial thrombosis, it was of interest to evaluate whether platelet adhesion under dynamic rheological condition is gender-related or not. However, in our study, platelet adhesion did not exhibit a significant difference between men and women (p > 0.05.), neither expressed as an absolute adhesion nor expressed as a relative adhesion. As shown in the results, in experiments with immobilized fibrinogen, women surprisingly showed consistently higher adherence at each shear rates and at each time point but without statistical significance (Table 2). This difference was constant under venous flow conditions (50 s-1, average 22%) and continuously declined along the perfusion time under arterial flow conditions (at 15 sec 25% and at 5 min 11%). Postmenopausal women showed a slightly higher platelet adhesion compared to premenopausal but without statistical significance. No significant correlation was found either between platelet adhesion and age, related to gender either.
In two very interesting studies, Miller et al. explored the adhesive properties of platelet under static and dynamic flow condition in regard to the gender and menopausal status [20, 21]. In static experiments the authors found out that platelet from women showed a higher adhesion activity than those in men. This difference increased in postmenopausal women. Simultaneously, women on ERT showed a significantly increased platelet adhesion rate compared to the premenopausal or postmenopausal women without ERT. In contrast to static experiments, in the flow studies conducted at 25 s-1 (extreme low flow) with platelets ex-vivo preincubated with estrogen, a decreased rate of platelet adhesion onto fibronectin was observed .
Boudoulas et al  tried to explain this controversy of ERT indicating that the benefit of estrogen could be impacted in regard to the HPA-1 polymorphism. In the aggregation study, the author described that only platelets with HPA-1b allele had shown the benefits of estrogen supplementation (reduced aggregation).
These findings could not be confirmed in our study. Firstly, we did not found any significant difference in platelet aggregation in regard to the HPA-1 polymorphism and secondly, no significant difference in platelet adhesion was observed between women and men in regard to the HPA-1 polymorphism neither at venous nor at arterial flow conditions.
Antoher possible explanation was recently given by Tong et al . The author reported that reduction activity of estrogen sulfotransferase (EST), due to increasing estrogen concentration and its bioavilability induce prothrombotic state. In animal model with generated EST knockout mice (Sult 1-/-) a significantly higher incidence of placental thrombosis and spontaneous fetal loss, caused by an estrogen excess, was observed. The additional analysis of knockout mice showed induced focal (placental) tissue factor expression as well as increased level of procoagulant factors VII, X, XII and XIII. This phenomenom was abolished through administration of low molecular weight heparin and/or related antiestrogen substance. It seems that this prothrombotic effect is restricted to the venose thrombosis, while platelets reactivity was only moderate enhanced.
Platelet adhesion onto immobilized fibrinogen under arterial and venous in-vitro flow conditions did not exhibit a significant difference between men and women. Platelet adhesion between women and men did not differ significantly with regard to the HPA-1 polymorphism.
This work was supported by the Deutsche Forschungsgemeinschaft, Sonderforschungsbereich 612, TP B2. Additional support was provided by the Biological Medical Research Center, Heinrich Heine University, Düsseldorf.
- Rauch U, Osende JI, Fuster V, Badimon JJ, Fayad Z, Chesebro JH: Thrombus formation on atherosclerotic plaques: pathogenesis and clinical consequences. Ann Intern Med 2001, 134: 224-238.View ArticlePubMedGoogle Scholar
- Viles-Gonzalez JF, Fuster V, Badimon JJ: Atherothrombosis: a widespread disease with unpredictable and life-threatening consequences. Eur Heart J 2004, 25: 1197-1207. 10.1016/j.ehj.2004.03.011View ArticlePubMedGoogle Scholar
- O'Donnell CJ, Larson MG, Feng D, Sutherland PA, Lindpaintner K, Myers RH, D'Agostino RA, Levy D, Tofler GH, Framingham Heart Study: Genetic and environmental contributions to platelet aggregation: the Framingham heart study. Circulation 2001, 103: 3051-3055.View ArticlePubMedGoogle Scholar
- Williams MS, Bray PF: Genetics of arterial prothrombotic risk states. Exp Biol Med 2001, 226: 409-401.Google Scholar
- Ruggeri ZM: Platelets in atherothrombosis. Nature Medicine 2002, 8: 1227-1234. 10.1038/nm1102-1227View ArticlePubMedGoogle Scholar
- Savage B, Saldivar E, Ruggeri ZM: Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell 1996, 84: 289-297. 10.1016/S0092-8674(00)80983-6View ArticlePubMedGoogle Scholar
- Bar J, Tepper R, Fuchs J, Pardo Y, Goldberger S, Ovadia J: The effect of estrogen replacement therapy on platelet aggregation and adenosine triphosphate release in postmenopausal women. Obstet Gynecol 1993, 81: 261-264.PubMedGoogle Scholar
- Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998, 280: 605-613. 10.1001/jama.280.7.605View ArticlePubMedGoogle Scholar
- Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J, Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002, 288: 321-333. 10.1001/jama.288.3.321View ArticlePubMedGoogle Scholar
- Wassertheil-Smoller S, Hendrix SL, Limacher M, Heiss G, Kooperberg C, Baird A, Kotchen T, Curb JD, Black H, Rossouw JE, Aragaki A, Safford M, Stein E, Laowattana S, Mysiw WJ, WHI Investigators: Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 2003, 289: 2673-2684. 10.1001/jama.289.20.2673View ArticlePubMedGoogle Scholar
- Zaidi TN, McIntire LV, Farrell DH, Thiagarajan P: Adhesion of platelets to surface-bound fibrinogen under flow. Blood 1996, 88: 2967-2972.PubMedGoogle Scholar
- Shattil SJ: Function and regulation of the β3 integrins in hemostasis and vascular biology. Thromb Haemostas 1995, 74: 149-155.Google Scholar
- Bini A, Kudryk BJ: Fibrinogen in human atherosclerosis. Ann NY Acad Sci 1995, 748: 461-471.View ArticlePubMedGoogle Scholar
- Cohen SA, Trikha M, Mascelli MA: Potential future clinical applications for the GPIIb/IIIa antagonist, abciximab in thrombosis, vascular and oncological indications. Pathol Oncol Res 2000, 6: 163-174.View ArticlePubMedGoogle Scholar
- Nauck MS, Gierens H, Nauck MA, Marz W, Wieland H: Rapid genotyping of human platelet antigen 1 (HPA-1) with fluorophore-labelled hybridization probes on the LightCycler. Br J Haematol 1999, 105: 803-810. 10.1046/j.1365-2141.1999.01427.xView ArticlePubMedGoogle Scholar
- van Kooten TG, Schakenraad JM, Van der Mei HC, Busscher HJ: Development and use of a parallel-plate flow chamber for studying cellular adhesion to solid surfaces. J Biomed Mater Res 1992, 26: 725-738. 10.1002/jbm.820260604View ArticlePubMedGoogle Scholar
- Malek AM, Alper SL, Izumo S: Hemodynamic shear stress and ist role in atherosclerosis. JAMA 1999, 282: 2035-2042. 10.1001/jama.282.21.2035View ArticlePubMedGoogle Scholar
- de Voogt HJ, Smith PH, Pavone-Macaluso M, de Pauw M, Suciu S: Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer trials 30761 and 30762. J Urol 1986, 135: 303-307.PubMedGoogle Scholar
- Grady D, Wenger NK, Herrington D, Khan S, Furberg C, Hunninghake D, Vittinghoff E, Hulley S: Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med 2000, 132: 689-696.View ArticlePubMedGoogle Scholar
- Miller ME, Dores GM, Thorpe SL, Akerley WL: Paradoxical influence of estrogenic hormones on platelet-endothelial cell interactions. Thromb Res 1994, 74: 577-594. 10.1016/0049-3848(94)90215-1View ArticlePubMedGoogle Scholar
- Miller ME, Thorpe SL, Dores GM: Influence of hormones on platelet intracellular calcium. Thromb Res 1995, 77: 515-530. 10.1016/0049-3848(95)00027-5View ArticlePubMedGoogle Scholar
- Boudoulas KD, Cooke GE, Roos CM, Bray PF, Goldschmidt-Clermont PJ: The PlA polymorphism of glycoprotein IIIa functions as a modifier for the effect of estrogen on platelet aggregation. Arch Pathol Lab Med 2001, 125: 112-115.PubMedGoogle Scholar
- Tong MH, Jiang H, Liu P, Lawson JA, Brass LF, Song WC: Spontaneous fetal loss caused by placental thrombosis in estrogen sulfotransferase-deficient mice. Nat Med 2005, 11: 153-159. 10.1038/nm1184View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.